NIP
EGRX

Nicholas Investment Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Nicholas Investment Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-37,254
Closed -$2.95M – 298
2016
Q4 		$2.95M Buy
+37,254
New +$2.71M 0.22% 188
2016
Q1 		– Sell
-48,556
Closed -$4.3M – 341
2015
Q4 		$4.3M Sell
48,556
-4,513
-9% -$356K 0.3% 140
2015
Q3 		$3.93M Buy
53,069
+1,314
+3% +$109K 0.28% 146
2015
Q2 		$4.18M Sell
51,755
-1,945
-4% -$127K 0.27% 133
2015
Q1 		$2.25M Buy
+53,700
New +$1.52M 0.14% 253

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Nicholas Investment Partners's EGRX Position: Q1 2017 in Review

Nicholas Investment Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2017, closing a stake of 37,254 shares — an estimated $2.95M sold.

Nicholas Investment Partners first reported a position in EGRX in Q1 2015 and held it in 5 quarters. The position peaked at $4.3M in Q4 2015. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

  • Nicholas Investment Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Nicholas Investment Partners sold 37,254 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $2.95M.
  • Nicholas Investment Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 5 quarters.
  • Nicholas Investment Partners's Eagle Pharmaceuticals, Inc. position peaked at $4.3M in Q4 2015.
  • 147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on Nicholas Investment Partners's 13F filing for Q1 2017, filed 15 May 2017.